CoChat

Multicenter, randomized, double‐blind phase 2 trial of FOLFIRI with regorafenib or placebo as second‐line therapy for metastatic colorectal cancer

Open access
Sanoff, Hanna K., Goldberg, Richard M., Ivanova, Anastasia, O'Reilly, Seamus, Kasbari, Samer S., Kim, Richard D., McDermott, Ray, Moore, Dominic T., Zamboni, William, Grogan, William, Cohn, Allen Lee, Bekaii‐Saab, Tanios S., Leonard, Gregory, Ryan, Theresa, Olowokure, Olugbenga O., Fernando, Nishan H., McCaffrey, John, El‐Rayes, Bassel F., Horgan, Anne M., Sherrill, Gary Bradley, Yacoub, George Hosni, O'Neil, Bert H. · 2018 · Cancer
Cited by 38

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Regorafenib, a multikinase inhibitor that inhibits angiogenesis, growth, and proliferation, prolongs survival as monotherapy in patients with refractory colorectal cancer. This international, double‐blind, placebo‐controlled, multicenter trial assessed the efficacy of regorafenib with folinic acid, fluorouracil, and irinotecan (FOLFIRI) as a second‐line treatment for metastatic colorectal cancer. METHODS: Patients with metastatic colorectal cancer who progressed on first‐line oxaliplatin and fluoropyrimidine enrolled at 45 sites in the United States and Ireland. Patients, stratified by prior bevacizumab use, were randomized 2:1 to regorafenib or placebo. The treatment consisted of FOLFIRI on days 1 and 2 and days 15 and 16 with 160 mg of regorafenib or placebo on days 4 to 10 and days 18 to 24 of every 28‐day cycle. Crossover was not allowed. The primary endpoint was progression‐free survival (PFS). Under the assumption of a 75% event rate, 180 patients were required for 135 events to achieve 90% power to detect a hazard ratio (HR) of 0.65 with a 1‐sided α value of .1. RESULTS: One hundred eighty‐one patients were randomized (120 to regorafenib‐FOLFIRI and 61 to placebo‐FOLFIRI) with a median age of 62 years. Among these, 117 (65%) received prior bevacizumab or aflibercept. PFS was longer with regorafenib‐FOLFIRI than placebo‐FOLFIRI (median, 6.1 vs 5.3 months; HR, 0.73; 95% confidence interval [CI], 0.53‐1.01; log‐rank P = .056). The median overall survival was not longer (HR, 1.01; 95% CI, 0.71‐1.44). The response rate was higher with regorafenib‐FOLFIRI (34%; 95% CI, 25%‐44%) than placebo‐FOLFIRI (21%; 95% CI, 11%‐33%; P = .07). Grade 3/4 adverse events with a >5% absolute increase from regorafenib included diarrhea, neutropenia, febrile neutropenia, hypophosphatemia, and hypertension. CONCLUSIONS: The addition of regorafenib to FOLFIRI as second‐line therapy for metastatic colorectal cancer only modestly prolonged PFS over FOLFIRI alone. Cancer 2018. © 2018 American Cancer Society .

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.31552

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 38

Metadata

Authors
Sanoff, H. K., Goldberg, R. M., Ivanova, A., O'Reilly, S., Kasbari, S. S., Kim, R. D., McDermott, R., Moore, D. T., Zamboni, W., Grogan, W., Cohn, A. L., Bekaii‐Saab, T. S., Leonard, G., Ryan, T., Olowokure, O. O., Fernando, N. H., McCaffrey, J., El‐Rayes, B. F., Horgan, A. M., Sherrill, G. B., Yacoub, G. H., & O'Neil, B. H.
Venue
Cancer
Publisher
Wiley
Published
2018-06-15
Volume
124
Issue
15
Pages
3118-3126
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W2808431530
Cited by
38
References
8
FWCI
1.43
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.